JP2014503189A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2014503189A5 JP2014503189A5 JP2013535578A JP2013535578A JP2014503189A5 JP 2014503189 A5 JP2014503189 A5 JP 2014503189A5 JP 2013535578 A JP2013535578 A JP 2013535578A JP 2013535578 A JP2013535578 A JP 2013535578A JP 2014503189 A5 JP2014503189 A5 JP 2014503189A5
- Authority
- JP
- Japan
- Prior art keywords
- antibody
- molecule
- composition
- human her3
- composition according
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 101710100969 Receptor tyrosine-protein kinase erbB-3 Proteins 0.000 claims 27
- 102100029986 Receptor tyrosine-protein kinase erbB-3 Human genes 0.000 claims 27
- 239000000203 mixture Substances 0.000 claims 27
- 239000008194 pharmaceutical composition Substances 0.000 claims 5
- 125000003275 alpha amino acid group Chemical group 0.000 claims 2
- 238000012258 culturing Methods 0.000 claims 2
- 150000007523 nucleic acids Chemical class 0.000 claims 2
- 102000039446 nucleic acids Human genes 0.000 claims 2
- 108020004707 nucleic acids Proteins 0.000 claims 2
- 102000001301 EGF receptor Human genes 0.000 claims 1
- 108060006698 EGF receptor Proteins 0.000 claims 1
- 101001010819 Homo sapiens Receptor tyrosine-protein kinase erbB-3 Proteins 0.000 claims 1
- 206010028980 Neoplasm Diseases 0.000 claims 1
- 230000001093 anti-cancer Effects 0.000 claims 1
- 230000003796 beauty Effects 0.000 claims 1
- 230000015572 biosynthetic process Effects 0.000 claims 1
- 201000011510 cancer Diseases 0.000 claims 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 1
- 208000035475 disorder Diseases 0.000 claims 1
- 229940079593 drug Drugs 0.000 claims 1
- 239000003814 drug Substances 0.000 claims 1
- 239000013604 expression vector Substances 0.000 claims 1
- 230000014509 gene expression Effects 0.000 claims 1
- 239000000833 heterodimer Substances 0.000 claims 1
- 102000057750 human ERBB3 Human genes 0.000 claims 1
- 229940127121 immunoconjugate Drugs 0.000 claims 1
- 230000001939 inductive effect Effects 0.000 claims 1
- 238000004519 manufacturing process Methods 0.000 claims 1
- 238000000034 method Methods 0.000 claims 1
- 239000002773 nucleotide Substances 0.000 claims 1
- 125000003729 nucleotide group Chemical group 0.000 claims 1
- 230000002018 overexpression Effects 0.000 claims 1
- 239000000546 pharmaceutical excipient Substances 0.000 claims 1
Applications Claiming Priority (9)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US40878210P | 2010-11-01 | 2010-11-01 | |
| DKPA201000988 | 2010-11-01 | ||
| US61/408,782 | 2010-11-01 | ||
| DKPA201000988 | 2010-11-01 | ||
| DKPA201100672 | 2011-09-05 | ||
| DKPA201100672 | 2011-09-05 | ||
| US201161531407P | 2011-09-06 | 2011-09-06 | |
| US61/531,407 | 2011-09-06 | ||
| PCT/IB2011/054835 WO2012059858A1 (en) | 2010-11-01 | 2011-10-31 | Anti-her3 antibodies and compositions |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2014503189A JP2014503189A (ja) | 2014-02-13 |
| JP2014503189A5 true JP2014503189A5 (enExample) | 2014-12-18 |
| JP6186277B2 JP6186277B2 (ja) | 2017-08-23 |
Family
ID=59014867
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2013535578A Expired - Fee Related JP6186277B2 (ja) | 2010-11-01 | 2011-10-31 | 抗ｈｅｒ３抗体および組成物 |
| JP2013535577A Expired - Fee Related JP6033783B2 (ja) | 2010-11-01 | 2011-10-31 | Ｐａｎ−ｈｅｒ抗体組成物 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2013535577A Expired - Fee Related JP6033783B2 (ja) | 2010-11-01 | 2011-10-31 | Ｐａｎ−ｈｅｒ抗体組成物 |
Country Status (13)
| Country | Link |
|---|---|
| US (1) | US9217039B2 (enExample) |
| EP (3) | EP3156421B1 (enExample) |
| JP (2) | JP6186277B2 (enExample) |
| KR (2) | KR101862832B1 (enExample) |
| AU (2) | AU2011324870B2 (enExample) |
| CA (2) | CA2816520C (enExample) |
| DK (1) | DK2635604T3 (enExample) |
| ES (2) | ES2692379T3 (enExample) |
| IL (2) | IL225953A0 (enExample) |
| MX (2) | MX347981B (enExample) |
| PL (1) | PL2635604T3 (enExample) |
| TW (1) | TW201231066A (enExample) |
| WO (2) | WO2012059858A1 (enExample) |
Families Citing this family (36)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN102137874B (zh) * | 2008-08-29 | 2015-02-18 | 西福根有限公司 | 抗表皮生长因子受体的重组抗体组合物 |
| EP2337800B1 (en) | 2008-09-15 | 2013-10-02 | Yeda Research and Development Co. Ltd. | Antibody combinations and use of same for treating cancer |
| CA2782571C (en) | 2009-12-22 | 2018-01-23 | Roche Glycart Ag | Anti-her3 antibodies and uses thereof |
| US9155802B2 (en) | 2010-11-01 | 2015-10-13 | Symphogen A/S | Pan-HER antibody composition |
| EP3156421B1 (en) | 2010-11-01 | 2018-06-06 | Symphogen A/S | Pan-her antibody composition |
| US20150231238A1 (en) * | 2011-03-15 | 2015-08-20 | Merrimack Pharmaceuticals, Inc. | Overcoming resistance to erbb pathway inhibitors |
| EP2710038B1 (en) * | 2011-05-16 | 2018-01-17 | Yeda Research and Development Co. Ltd. | COMBINATIONS OF ANTI ErbB ANTIBODIES FOR THE TREATMENT OF CANCER |
| CA2838695C (en) * | 2011-07-01 | 2017-02-14 | Amgen Inc. | Mammalian cell culture |
| AU2012340766B2 (en) | 2011-11-23 | 2018-05-10 | Medimmune, Llc | Binding molecules specific for HER3 and uses thereof |
| WO2013148315A1 (en) * | 2012-03-27 | 2013-10-03 | Genentech, Inc. | Diagnosis and treatments relating to her3 inhibitors |
| MX358728B (es) * | 2012-05-02 | 2018-09-03 | Symphogen As | Composiciones de anticuerpos pan-receptor del factor de crecimiento epidermico humano (pan-her) humanizados. |
| US9180185B2 (en) | 2013-01-11 | 2015-11-10 | Hoffman-La Roche Inc. | Combination therapy of anti-HER3 antibodies |
| SI3508502T1 (sl) * | 2013-09-20 | 2023-07-31 | Bristol-Myers Squibb Company | Kombinacija anti-lag-3 protiteles in anti-pd-1 protiteles za zdravljenje tumorjev |
| US11305012B2 (en) | 2013-09-24 | 2022-04-19 | Medimmune, Llc | Binding molecules specific for HER3 and uses thereof |
| US10745490B2 (en) | 2014-04-11 | 2020-08-18 | Celldex Therapeutics, Inc. | Anti-ErbB antibodies and methods of use thereof |
| US9840553B2 (en) | 2014-06-28 | 2017-12-12 | Kodiak Sciences Inc. | Dual PDGF/VEGF antagonists |
| US10526416B2 (en) | 2014-09-08 | 2020-01-07 | Yeda Research And Development Co. Ltd. | Anti-HER3 antibodies and uses of same |
| JP2017534574A (ja) | 2014-09-08 | 2017-11-24 | イェダ リサーチ アンド ディベロップメント カンパニー リミテッドＹｅｄａ Ｒｅｓｅａｒｃｈ Ａｎｄ Ｄｅｖｅｌｏｐｍｅｎｔ Ｃｏ．Ｌｔｄ． | チロシンキナーゼ阻害薬（ｔｋｉ）に耐性のがんを処置するための組成物および方法 |
| CN107001471B (zh) | 2014-09-16 | 2022-01-18 | 西福根有限公司 | 抗met抗体和组合物 |
| EP3176183A1 (en) | 2015-12-02 | 2017-06-07 | Yeda Research and Development Co. Ltd | Compositions and methods for treating cancer not resistant to a tyrosine kinase inhibitor (tki) |
| MA43416A (fr) | 2015-12-11 | 2018-10-17 | Regeneron Pharma | Méthodes pour ralentir ou empêcher la croissance de tumeurs résistantes au blocage de l'egfr et/ou d'erbb3 |
| BR112018013407A2 (en) | 2015-12-30 | 2018-12-18 | Kodiak Sciences Inc. | antibodies and conjugates thereof |
| US20190151346A1 (en) | 2016-05-10 | 2019-05-23 | INSERM (Institute National de la Santé et de la Recherche Médicale) | Combinations therapies for the treatment of cancer |
| CA3185303A1 (en) | 2017-04-05 | 2018-10-11 | Symphogen A/S | Combination therapies targeting pd-a, tim-3, and lag-3 |
| KR20240155979A (ko) | 2017-05-30 | 2024-10-29 | 브리스톨-마이어스 스큅 컴퍼니 | 항-lag-3 항체 또는 항-lag-3 항체 및 항-pd-1 또는 항-pd-l1 항체를 포함하는 조성물 |
| KR102713203B1 (ko) | 2017-05-30 | 2024-10-10 | 브리스톨-마이어스 스큅 컴퍼니 | Lag-3 양성 종양의 치료 |
| SG11202008242XA (en) | 2018-03-02 | 2020-09-29 | Kodiak Sciences Inc | Il-6 antibodies and fusion constructs and conjugates thereof |
| AU2019336197A1 (en) | 2018-09-07 | 2021-02-18 | Pfizer Inc. | Anti-avb8 antibodies and compositions and uses thereof |
| CN114426578B (zh) * | 2019-02-14 | 2025-03-21 | 美勒斯公司 | 结合egfr、her2及her3的结合部分的组合 |
| CA3130248A1 (en) * | 2019-02-14 | 2020-08-20 | Merus N.V. | Combinations of binding moieties that bind egfr, her2 and her3. |
| US20220259290A1 (en) * | 2019-07-24 | 2022-08-18 | Japan Science And Technology Agency | Innovative production technique for antibody-enzyme |
| US11912784B2 (en) | 2019-10-10 | 2024-02-27 | Kodiak Sciences Inc. | Methods of treating an eye disorder |
| AU2021364837A1 (en) | 2020-10-23 | 2023-05-25 | Bristol-Myers Squibb Company | Lag-3 antagonist therapy for lung cancer |
| JP7623497B2 (ja) | 2020-12-31 | 2025-01-28 | サノフイ | ＮＫｐ４６およびＣＤ１２３に結合する多機能性ナチュラルキラー（ＮＫ）細胞エンゲージャ |
| TW202413419A (zh) | 2022-05-27 | 2024-04-01 | 法商賽諾菲公司 | 與ｎｋｐ４６和ｂｃｍａ變體結合之具有ｆｃ工程化的自然殺手（ｎｋ）細胞接合物 |
| EP4713360A1 (en) | 2023-05-19 | 2026-03-25 | Les Laboratoires Servier | Anti-met antibodies, antibody-drug conjugates, compositions and uses thereof |
Family Cites Families (33)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| IL126303A (en) | 1996-03-27 | 2002-05-23 | Genentech Inc | ErbB3 ANTIBODIES |
| US5968511A (en) | 1996-03-27 | 1999-10-19 | Genentech, Inc. | ErbB3 antibodies |
| AUPQ105799A0 (en) * | 1999-06-18 | 1999-07-08 | Victor Chang Cardiac Research Institute, The | Cell growth inhibition |
| ES2637801T3 (es) | 2000-04-11 | 2017-10-17 | Genentech, Inc. | Anticuerpos multivalentes y usos de los mismos |
| EP1283053A1 (en) | 2001-08-09 | 2003-02-12 | Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. | Inhibitors of HER3 activity |
| MXPA05006724A (es) | 2003-01-07 | 2005-09-08 | Symphogen As | Metodo para producir proteinas policlonales recombinantes. |
| WO2004087763A1 (ja) * | 2003-03-31 | 2004-10-14 | Chugai Seiyaku Kabushiki Kaisha | Ｃｄ２２に対する改変抗体およびその利用 |
| TWI333977B (en) | 2003-09-18 | 2010-12-01 | Symphogen As | Method for linking sequences of interest |
| AU2005263334C1 (en) | 2004-07-20 | 2011-01-20 | Symphogen A/S | A procedure for structural characterization of a recombinant polyclonal protein or a polyclonal cell line |
| KR20110050567A (ko) | 2004-07-22 | 2011-05-13 | 제넨테크, 인크. | Ｈｅｒ２ 항체 조성물 |
| US20060121044A1 (en) | 2004-12-07 | 2006-06-08 | Genentech, Inc. | Selecting patients for therapy with a her inhibitor |
| AR056857A1 (es) * | 2005-12-30 | 2007-10-24 | U3 Pharma Ag | Anticuerpos dirigidos hacia her-3 (receptor del factor de crecimiento epidérmico humano-3) y sus usos |
| WO2008031531A1 (en) * | 2006-09-15 | 2008-03-20 | F. Hoffmann-La Roche Ag | Tumor therapy with a combination of anti-her2 antibodies |
| PL2129396T3 (pl) * | 2007-02-16 | 2014-02-28 | Merrimack Pharmaceuticals Inc | Przeciwciała przeciw ERBB3 i ich zastosowania |
| MX338151B (es) | 2007-03-01 | 2016-04-05 | Symphogen As | Composiciones de anticuerpo recombinante anti-receptor de factor de crecimiento epidermico. |
| PL2152872T3 (pl) | 2007-05-25 | 2011-03-31 | Symphogen As | Sposób wytwarzania rekombinowanego białka poliklonalnego |
| NZ584684A (en) | 2007-11-22 | 2012-10-26 | Symphogen As | A method for characterization of a recombinant polyclonal protein |
| KR20110016899A (ko) | 2008-04-23 | 2011-02-18 | 심포젠 에이/에스 | 폴리클로날 단백질을 제조하는 방법 |
| KR20110044905A (ko) | 2008-08-15 | 2011-05-02 | 메리맥 파마슈티컬즈, 인크. | 치료제에 대한 세포의 반응을 예측하는 방법 및 시스템 |
| CN102137874B (zh) * | 2008-08-29 | 2015-02-18 | 西福根有限公司 | 抗表皮生长因子受体的重组抗体组合物 |
| MX2011003480A (es) * | 2008-10-06 | 2011-04-21 | Symphogen As | Metodo para identificar y seleccionar candidatos de farmaco para productos de farmacos de combinacion. |
| NZ594665A (en) * | 2009-03-20 | 2013-08-30 | Genentech Inc | Bispecific anti-her antibodies |
| MX2011010166A (es) | 2009-04-07 | 2011-10-11 | Roche Glycart Ag | Anticuerpos biespecificos anti-erbb-3/anti-c-met. |
| CN102369214B (zh) | 2009-04-07 | 2019-04-12 | 罗氏格黎卡特股份公司 | 三价、双特异性抗体 |
| AU2010242914B2 (en) | 2009-04-29 | 2014-11-13 | Trellis Bioscience, Llc | Improved antibodies immunoreactive with heregulin-coupled HER3 |
| SG177560A1 (en) * | 2009-07-06 | 2012-03-29 | Hoffmann La Roche | Bi-specific digoxigenin binding antibodies |
| SG178509A1 (en) * | 2009-08-21 | 2012-04-27 | Merrimack Pharmaceuticals Inc | Antibodies against the ectodomain of erbb3 and uses thereof |
| CA2775573A1 (en) | 2009-10-09 | 2011-04-14 | Merck Sharp & Dohme Corp. | Generation, characterization and uses thereof of anti-her 3 antibodies |
| KR101806323B1 (ko) | 2009-11-13 | 2017-12-07 | 다이이치 산쿄 유럽 게엠베하 | Ｈｅｒ-３ 관련 질병을 치료하거나 예방하기 위한 물질 및 방법 |
| TW201141519A (en) | 2010-03-04 | 2011-12-01 | Symphogen As | Anti-HER2 antibodies and compositions |
| BR112012025730B1 (pt) | 2010-04-09 | 2020-12-08 | Aveo Pharmaceuticals, Inc | anticorpo isolado que se liga ao erbb3 humano, seus usos, seu processo de produção e vetor de expressão |
| PL2606070T3 (pl) * | 2010-08-20 | 2017-06-30 | Novartis Ag | Przeciwciała dla receptora epidermalnego czynnika wzrostu 3 (her3) |
| EP3156421B1 (en) | 2010-11-01 | 2018-06-06 | Symphogen A/S | Pan-her antibody composition |
-
2011
- 2011-10-31 EP EP16200853.6A patent/EP3156421B1/en not_active Not-in-force
- 2011-10-31 PL PL11797354T patent/PL2635604T3/pl unknown
- 2011-10-31 ES ES11837656.5T patent/ES2692379T3/es active Active
- 2011-10-31 MX MX2013004899A patent/MX347981B/es active IP Right Grant
- 2011-10-31 AU AU2011324870A patent/AU2011324870B2/en not_active Ceased
- 2011-10-31 JP JP2013535578A patent/JP6186277B2/ja not_active Expired - Fee Related
- 2011-10-31 JP JP2013535577A patent/JP6033783B2/ja not_active Expired - Fee Related
- 2011-10-31 ES ES11797354.5T patent/ES2616961T3/es active Active
- 2011-10-31 CA CA2816520A patent/CA2816520C/en not_active Expired - Fee Related
- 2011-10-31 WO PCT/IB2011/054835 patent/WO2012059858A1/en not_active Ceased
- 2011-10-31 EP EP11797354.5A patent/EP2635604B1/en not_active Not-in-force
- 2011-10-31 AU AU2011324871A patent/AU2011324871B2/en not_active Ceased
- 2011-10-31 US US13/882,807 patent/US9217039B2/en not_active Expired - Fee Related
- 2011-10-31 CA CA2816519A patent/CA2816519C/en not_active Expired - Fee Related
- 2011-10-31 DK DK11797354.5T patent/DK2635604T3/en active
- 2011-10-31 KR KR1020137013561A patent/KR101862832B1/ko not_active Expired - Fee Related
- 2011-10-31 WO PCT/IB2011/054834 patent/WO2012059857A2/en not_active Ceased
- 2011-10-31 MX MX2013004897A patent/MX348637B/es active IP Right Grant
- 2011-10-31 KR KR1020137013552A patent/KR101773120B1/ko not_active Expired - Fee Related
- 2011-10-31 EP EP11837656.5A patent/EP2635605B1/en not_active Not-in-force
- 2011-11-01 TW TW100139897A patent/TW201231066A/zh unknown
-
2013
- 2013-04-25 IL IL225953A patent/IL225953A0/en unknown
- 2013-04-25 IL IL225954A patent/IL225954B/en active IP Right Grant
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2014503189A5 (enExample) | ||
| JP2014503188A5 (enExample) | ||
| FI3487882T3 (fi) | Gprc5d-vasta-aineita, bispesifisiä antigeeniä sitovia molekyylejä, jotka sitovat gprc5d:tä ja cd3:a, sekä niiden käyttötapoja | |
| JP2020023523A5 (enExample) | ||
| RU2504553C2 (ru) | Антитела к her | |
| JP2017534259A5 (enExample) | ||
| JP2010526028A5 (enExample) | ||
| RU2016115866A (ru) | Мультиспецифические антитела с обменянными доменами и одинаковыми вариабельными доменами легкой цепи | |
| JP2014502955A5 (enExample) | ||
| RU2014103784A (ru) | Антитело, блокирующее agr2, и его применение | |
| JP2013520984A5 (enExample) | ||
| RU2014109039A (ru) | Биспецифические антигенсвязывающие молекулы | |
| JP2018503380A5 (enExample) | ||
| JP2014509510A5 (enExample) | ||
| JP2010531140A5 (enExample) | ||
| FI3328888T3 (fi) | Anti-PSMA-vasta-aineita, bispesifisiä antigeeniä sitovia molekyylejä, jotka sitovat PSMA:ta ja CD3:a, ja niiden käyttöjä | |
| SI2753646T1 (en) | Anti-CD40 antibodies, uses and methods | |
| RU2014149553A (ru) | Биспецифические анти-vegf/анти-ang-2 антитела | |
| RU2014149681A (ru) | Антитела с множественной специфичностью | |
| JP2018509175A5 (enExample) | ||
| RU2013102225A (ru) | АНТИТЕЛА ПРОТИВ Axl И СПОСОБЫ ИХ ПРИМЕНЕНИЯ | |
| JP2013527761A5 (enExample) | ||
| JP2015501814A5 (enExample) | ||
| JP2009545325A5 (enExample) | ||
| JP2014526898A5 (enExample) |